Arrowhead Pharmaceuticals develops and commercializes RNA interference medicines that silence genes associated with intractable diseases. The company’s TRiM™ platform is used to design targeted RNAi therapeutics for tissues including liver, lung, muscle, adipose and central nervous system tissue.
Recurring ARWR news covers REDEMPLO® (plozasiran), an siRNA medicine approved in the United States and Australia as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome. Company updates also address plozasiran data across hypertriglyceridemia, regulatory actions in additional geographies, pricing and market-access strategy, fiscal results, investor events, and clinical or partnering developments involving programs such as ARO-PNPLA3, ARO-INHBE and ARO-ALK7.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced its participation in the Chardan Virtual 4th Annual Genetic Medicines Conference on October 6, 2020, at 1:30 p.m. EDT. Vince Anzalone, CFA, Arrowhead's VP and head of investor relations, will engage in a fireside chat presentation during this event. Presentation materials and webcast links will be available on the Events and Presentations section of their website. Arrowhead focuses on developing RNA interference-based therapies to combat intractable diseases.